Aptevo Therapeutics files 1-for-18 reverse stock split effective Dec 29, 2025

Aptevo Therapeutics Inc.

Reverse split ratio 1-for-18 approved by board Dec 17; effective Dec 29 at 5:01 PM ET.
Split-adjusted trading on Nasdaq begins Dec 30; new CUSIP 03835L702.
No fractional shares issued; cash in lieu; adjustments to options, warrants, RSUs.
Stockholders approved split on July 24, 2025 Special Meeting; range 1:6–1:22.
Forward-looking statements acknowledge risk of ability to continue as going concern.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Aptevo Therapeutics Inc.: Amendment to Certificate of Incorporation to effect a 1-for-18 reverse stock split (effective 2025-12-29).

Change: charter amendment
Effective: 2025-12-29

Exact text from the filing

Accordingly, on December 29, 2025, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect the Reverse Stock Split. The Amendment was effective at 5:01 p.m. Eastern Time on December 29, 2025 (the “Effective Time”).

View on SEC.gov

Browse all governance changes →

Aptevo Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-335497

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.